Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2018

Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer

Sandrine Caputo
Rita Brandão
Ana Vega
  • Fonction : Auteur
  • PersonId : 887296
Myriam Bronner
  • Fonction : Auteur
Danièle Muller
  • Fonction : Auteur
Inge Søkilde
  • Fonction : Auteur
Sophie Demontety
  • Fonction : Auteur
Uffe Birk Jensen
Nadia Boutry-Kryza
  • Fonction : Auteur
  • PersonId : 942109
Henriette Roed Nielsen
  • Fonction : Auteur
Amanda Spurdle
  • Fonction : Auteur
  • PersonId : 909895
Manuel Teixeira
  • Fonction : Auteur
Etienne Rouleau
  • Fonction : Auteur
  • PersonId : 889842

Résumé

Germline pathogenic variants in the BRCA2 gene are associated with a cumulative high risk of breast/ovarian cancer. Several BRCA2 variants result in complete loss of the exon-3 at the transcript level. The pathogenicity of these variants and the functional impact of loss of exon 3 have yet to be established. As a collaboration of the COVAR clinical trial group (France), and the ENIGMA consortium for investigating breast cancer gene variants, this study evaluated 8 BRCA2 variants resulting in complete deletion of exon 3. Clinical information for 39 families was gathered from Portugal, France, Denmark and Sweden. Multifactorial likelihood analyses were conducted using information from 293 patients, for 7 out of the 8 variants (including 6 intronic). For all variants combined the likelihood ratio in favor of causality was 4.39*1025. These results provide convincing evidence for the pathogenicity of all examined variants that lead to a total exon 3 skipping, and suggest that other variants that result in complete loss of exon 3 at the molecular level could be associated with a high risk of cancer comparable to that associated with classical pathogenic variants in BRCA1 or BRCA2 gene. In addition, our functional study shows, for the first time, that deletion of exon 3 impairs the ability of cells to survive upon Mitomycin-C treatment, supporting lack of function for the altered BRCA2 protein in these cells. Finally, this study demonstrates that any variant leading to expression of only BRCA2 delta-exon 3 will be associated with an increased risk of breast and ovarian cancer.
Fichier principal
Vignette du fichier
24671-345040-4-PB.pdf (2.55 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-01928011 , version 1 (25-07-2019)

Licence

Paternité

Identifiants

Citer

Sandrine Caputo, Mélanie Léoné, Francesca Damiola, Asa Ehlen, Aura Carreira, et al.. Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovarian cancer. Oncotarget, 2018, 9 (9), pp.17334-17348. ⟨10.18632/oncotarget.24671⟩. ⟨hal-01928011⟩
253 Consultations
75 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More